LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Enrichment of transgene integrations by transient CRISPR activation of a silent reporter gene.

    Mikkelsen, Nanna S / Hernandez, Sabina S / Jensen, Trine I / Schneller, Jessica L / Bak, Rasmus O

    Molecular therapy. Methods & clinical development

    2023  Volume 29, Page(s) 1–16

    Abstract: CRISPR-Cas-mediated site-specific integration of transgenes by homology-directed repair (HDR) is challenging, especially in primary cells, where inferior editing efficiency may impede the development of gene- and cellular therapies. Various strategies ... ...

    Abstract CRISPR-Cas-mediated site-specific integration of transgenes by homology-directed repair (HDR) is challenging, especially in primary cells, where inferior editing efficiency may impede the development of gene- and cellular therapies. Various strategies for enrichment of cells with transgene integrations have been developed, but most strategies either generate unwanted genomic scars or rely on permanent integration and expression of a reporter gene used for selection. However, stable expression of a reporter gene may perturb cell homeostasis and function. Here we develop a broadly applicable and versatile enrichment strategy by harnessing the capability of CRISPR activation (CRISPRa) to transiently induce expression of a therapeutically relevant reporter gene used for immunomagnetic enrichment. This strategy is readily adaptable to primary human T cells and CD34+ hematopoietic stem and progenitor cells (HSPCs), where enrichment of 1.8- to 3.3-fold and 3.2- to 3.6-fold was achieved, respectively. Furthermore, chimeric antigen receptor (CAR) T cells were enriched 2.5-fold and demonstrated improved cytotoxicity over non-enriched CAR T cells. Analysis of HDR integrations showed a proportion of cells harboring deletions of the transgene cassette arising either from impartial HDR or truncated adeno-associated virus (AAV) vector genomes. Nonetheless, this novel enrichment strategy expands the possibility to enrich for transgene integrations in research settings and in gene and cellular therapies.
    Language English
    Publishing date 2023-02-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2872938-9
    ISSN 2329-0501 ; 2329-0501
    ISSN (online) 2329-0501
    ISSN 2329-0501
    DOI 10.1016/j.omtm.2023.02.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Genome editing for inborn errors of metabolism: advancing towards the clinic.

    Schneller, Jessica L / Lee, Ciaran M / Bao, Gang / Venditti, Charles P

    BMC medicine

    2017  Volume 15, Issue 1, Page(s) 43

    Abstract: Inborn errors of metabolism (IEM) include many disorders for which current treatments aim to ameliorate disease manifestations, but are not curative. Advances in the field of genome editing have recently resulted in the in vivo correction of murine ... ...

    Abstract Inborn errors of metabolism (IEM) include many disorders for which current treatments aim to ameliorate disease manifestations, but are not curative. Advances in the field of genome editing have recently resulted in the in vivo correction of murine models of IEM. Site-specific endonucleases, such as zinc-finger nucleases and the CRISPR/Cas9 system, in combination with delivery vectors engineered to target disease tissue, have enabled correction of mutations in disease models of hemophilia B, hereditary tyrosinemia type I, ornithine transcarbamylase deficiency, and lysosomal storage disorders. These in vivo gene correction studies, as well as an overview of genome editing and future directions for the field, are reviewed and discussed herein.
    MeSH term(s) Gene Editing/methods ; Genetic Therapy/methods ; Humans ; Metabolism, Inborn Errors/genetics
    Language English
    Publishing date 2017-02-27
    Publishing country England
    Document type Journal Article ; Review
    ISSN 1741-7015
    ISSN (online) 1741-7015
    DOI 10.1186/s12916-017-0798-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Aberrant methylmalonylation underlies methylmalonic acidemia and is attenuated by an engineered sirtuin.

    Head, PamelaSara E / Myung, Sangho / Chen, Yong / Schneller, Jessica L / Wang, Cindy / Duncan, Nicholas / Hoffman, Pauline / Chang, David / Gebremariam, Abigael / Gucek, Marjan / Manoli, Irini / Venditti, Charles P

    Science translational medicine

    2022  Volume 14, Issue 646, Page(s) eabn4772

    Abstract: Organic acidemias such as methylmalonic acidemia (MMA) are a group of inborn errors of metabolism that typically arise from defects in the catabolism of amino and fatty acids. Accretion of acyl-CoA species is postulated to underlie disease ... ...

    Abstract Organic acidemias such as methylmalonic acidemia (MMA) are a group of inborn errors of metabolism that typically arise from defects in the catabolism of amino and fatty acids. Accretion of acyl-CoA species is postulated to underlie disease pathophysiology, but the mechanism(s) remain unknown. Here, we surveyed hepatic explants from patients with MMA and unaffected donors, in parallel with samples from various mouse models of methylmalonyl-CoA mutase deficiency. We found a widespread posttranslational modification, methylmalonylation, that inhibited enzymes in the urea cycle and glycine cleavage pathway in MMA. Biochemical studies and mouse genetics established that sirtuin 5 (SIRT5) controlled the metabolism of MMA-related posttranslational modifications. SIRT5 was engineered to resist acylation-driven inhibition via lysine to arginine mutagenesis. The modified SIRT5 was used to create an adeno-associated viral 8 (AAV8) vector and systemically delivered to mutant and control mice. Gene therapy ameliorated hyperammonemia and reduced global methylmalonylation in the MMA mice.
    MeSH term(s) Amino Acid Metabolism, Inborn Errors/genetics ; Amino Acid Metabolism, Inborn Errors/metabolism ; Amino Acid Metabolism, Inborn Errors/therapy ; Animals ; Genetic Therapy ; Humans ; Methylmalonyl-CoA Mutase/genetics ; Methylmalonyl-CoA Mutase/metabolism ; Mice ; Sirtuins/genetics
    Chemical Substances Sirtuins (EC 3.5.1.-) ; Methylmalonyl-CoA Mutase (EC 5.4.99.2)
    Language English
    Publishing date 2022-05-25
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural
    ZDB-ID 2518854-9
    ISSN 1946-6242 ; 1946-6234
    ISSN (online) 1946-6242
    ISSN 1946-6234
    DOI 10.1126/scitranslmed.abn4772
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: In vivo

    Schneller, Jessica L / Lee, Ciaran M / Venturoni, Leah E / Chandler, Randy J / Li, Ang / Myung, Sangho / Cradick, Thomas J / Hurley, Ayrea E / Lagor, William R / Bao, Gang / Venditti, Charles P

    Molecular therapy. Methods & clinical development

    2021  Volume 23, Page(s) 619–632

    Abstract: Methylmalonic acidemia (MMA) is a metabolic disorder most commonly caused by mutations in the methylmalonyl-CoA mutase ( ...

    Abstract Methylmalonic acidemia (MMA) is a metabolic disorder most commonly caused by mutations in the methylmalonyl-CoA mutase (
    Language English
    Publishing date 2021-11-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2872938-9
    ISSN 2329-0501 ; 2329-0501
    ISSN (online) 2329-0501
    ISSN 2329-0501
    DOI 10.1016/j.omtm.2021.11.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia.

    Chandler, Randy J / Venturoni, Leah E / Liao, Jing / Hubbard, Brandon T / Schneller, Jessica L / Hoffmann, Victoria / Gordo, Susana / Zang, Shengwen / Ko, Chih-Wei / Chau, Nelson / Chiang, Kyle / Kay, Mark A / Barzel, Adi / Venditti, Charles P

    Hepatology (Baltimore, Md.)

    2021  Volume 73, Issue 6, Page(s) 2223–2237

    Abstract: Background and aims: Adeno-associated viral (AAV) gene therapy has shown great promise as an alternative treatment for metabolic disorders managed using liver transplantation, but remains limited by transgene loss and genotoxicity. Our study aims to ... ...

    Abstract Background and aims: Adeno-associated viral (AAV) gene therapy has shown great promise as an alternative treatment for metabolic disorders managed using liver transplantation, but remains limited by transgene loss and genotoxicity. Our study aims to test an AAV vector with a promoterless integrating cassette, designed to provide sustained hepatic transgene expression and reduced toxicity in comparison to canonical AAV therapy.
    Approach and results: Our AAV vector was designed to insert a methylmalonyl-CoA mutase (MMUT) transgene into the 3' end of the albumin locus and tested in mouse models of methylmalonic acidemia (MMA). After neonatal delivery, we longitudinally evaluated hepatic transgene expression, plasma levels of methylmalonate, and the MMA biomarker, fibroblast growth factor 21 (Fgf21), as well as integration of MMUT in the albumin locus. At necropsy, we surveyed for AAV-related hepatocellular carcinoma (HCC) in all treated MMA mice and control littermates. AAV-mediated genome editing of MMUT into the albumin locus resulted in permanent hepatic correction in MMA mouse models, which was accompanied by decreased levels of methylmalonate and Fgf21, and improved survival without HCC. With time, levels of transgene expression increased and methylmalonate progressively decreased, whereas the number of albumin-MMUT integrations and corrected hepatocytes in MMA mice increased, but not in similarly treated wild-type animals. Additionally, expression of MMUT in the setting of MMA conferred a selective growth advantage upon edited cells, which potentiates the therapeutic response.
    Conclusions: In conclusion, our findings demonstrate that AAV-mediated, promoterless, nuclease-free genome editing at the albumin locus provides safe and durable therapeutic benefit in neonatally treated MMA mice.
    MeSH term(s) Amino Acid Metabolism, Inborn Errors/metabolism ; Amino Acid Metabolism, Inborn Errors/therapy ; Animals ; Animals, Newborn ; Biomarkers/blood ; Carcinoma, Hepatocellular/pathology ; Dependovirus/genetics ; Disease Models, Animal ; Fibroblast Growth Factors/blood ; Gene Editing/methods ; Genetic Therapy/methods ; Hepatocytes ; Liver Neoplasms/pathology ; Liver Transplantation ; Malonates/blood ; Methylmalonyl-CoA Mutase/genetics ; Methylmalonyl-CoA Mutase/metabolism ; Mice ; Mice, Inbred C57BL
    Chemical Substances Biomarkers ; Malonates ; fibroblast growth factor 21 ; Fibroblast Growth Factors (62031-54-3) ; malonic acid (9KX7ZMG0MK) ; Methylmalonyl-CoA Mutase (EC 5.4.99.2)
    Language English
    Publishing date 2021-05-21
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 604603-4
    ISSN 1527-3350 ; 0270-9139
    ISSN (online) 1527-3350
    ISSN 0270-9139
    DOI 10.1002/hep.31570
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia.

    An, Ding / Schneller, Jessica L / Frassetto, Andrea / Liang, Shi / Zhu, Xuling / Park, Ji-Sun / Theisen, Matt / Hong, Sue-Jean / Zhou, Jenny / Rajendran, Raj / Levy, Becca / Howell, Rebecca / Besin, Gilles / Presnyak, Vladimir / Sabnis, Staci / Murphy-Benenato, Kerry E / Kumarasinghe, E Sathyajith / Salerno, Timothy / Mihai, Cosmin /
    Lukacs, Christine M / Chandler, Randy J / Guey, Lin T / Venditti, Charles P / Martini, Paolo G V

    Cell reports

    2018  Volume 24, Issue 9, Page(s) 2520

    Language English
    Publishing date 2018-09-11
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 2649101-1
    ISSN 2211-1247 ; 2211-1247
    ISSN (online) 2211-1247
    ISSN 2211-1247
    DOI 10.1016/j.celrep.2018.08.049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia.

    An, Ding / Schneller, Jessica L / Frassetto, Andrea / Liang, Shi / Zhu, Xuling / Park, Ji-Sun / Theisen, Matt / Hong, Sue-Jean / Zhou, Jenny / Rajendran, Raj / Levy, Becca / Howell, Rebecca / Besin, Gilles / Presnyak, Vladimir / Sabnis, Staci / Murphy-Benenato, Kerry E / Kumarasinghe, E Sathyajith / Salerno, Timothy / Mihai, Cosmin /
    Lukacs, Christine M / Chandler, Randy J / Guey, Lin T / Venditti, Charles P / Martini, Paolo G V

    Cell reports

    2018  Volume 21, Issue 12, Page(s) 3548–3558

    Abstract: Isolated methylmalonic acidemia/aciduria (MMA) is a devastating metabolic disorder with poor outcomes despite current medical treatments. Like other mitochondrial enzymopathies, enzyme replacement therapy (ERT) is not available, and although promising, ... ...

    Abstract Isolated methylmalonic acidemia/aciduria (MMA) is a devastating metabolic disorder with poor outcomes despite current medical treatments. Like other mitochondrial enzymopathies, enzyme replacement therapy (ERT) is not available, and although promising, AAV gene therapy can be limited by pre-existing immunity and has been associated with genotoxicity in mice. To develop a new class of therapy for MMA, we generated a pseudoU-modified codon-optimized mRNA encoding human methylmalonyl-CoA mutase (hMUT), the enzyme most frequently mutated in MMA, and encapsulated it into biodegradable lipid nanoparticles (LNPs). Intravenous (i.v.) administration of hMUT mRNA in two different mouse models of MMA resulted in a 75%-85% reduction in plasma methylmalonic acid and was associated with increased hMUT protein expression and activity in liver. Repeat dosing of hMUT mRNA reduced circulating metabolites and dramatically improved survival and weight gain. Additionally, repeat i.v. dosing did not increase markers of liver toxicity or inflammation in heterozygote MMA mice.
    MeSH term(s) Administration, Intravenous ; Amino Acid Metabolism, Inborn Errors/therapy ; Animals ; Female ; Genetic Therapy/methods ; Humans ; Lipids/chemistry ; Liver/metabolism ; Male ; Methylmalonyl-CoA Mutase/genetics ; Methylmalonyl-CoA Mutase/metabolism ; Mice ; Nanoparticles/administration & dosage ; Nanoparticles/chemistry ; RNA, Messenger/genetics ; RNA, Messenger/metabolism
    Chemical Substances Lipids ; RNA, Messenger ; Methylmalonyl-CoA Mutase (EC 5.4.99.2)
    Language English
    Publishing date 2018-02-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2649101-1
    ISSN 2211-1247 ; 2211-1247
    ISSN (online) 2211-1247
    ISSN 2211-1247
    DOI 10.1016/j.celrep.2017.11.081
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top